Skip to main content

Advertisement

Table 1 Baseline characteristics for patients randomized to double-blind adalimumab (ADA) 40 mg every 2 weeks or tofacitinib 10 mg twice daily (BID) in the phase 3 study [10] and for the subgroup who then received open-label tofacitinib 10 mg BID in the extension study [13]

From: Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis

  Double-blind study Double-blind to open-label extensiona
ADA 40 mg Tofacitinib 10 mg ADA to tofacitinib Tofacitinib to tofacitinib
n = 204 n = 201 n = 107 n = 126
Female, n (%) 162 (79.4) 168 (83.6) 83 (77.6) 107 (84.9)
White, n (%) 148 (72.5) 143 (71.1) 90 (84.1) 98 (77.8)
Age in years, mean ± SD 52.5 ± 11.7 52.9 ± 11.8 52.2 ± 11.4 51.6 ± 11.2
Region of origin, %
 North America 25.5 24.9 16.8 20.6
 South America 2.9 1.5 4.7 1.6
 Europe 53.9 55.7 60.7 59.5
 Rest of world 17.6 17.9 17.8 18.3
Tender and swollen joints, mean
 Tender 26.7 26.1 28.0 25.6
 Swollen 16.4 15.8 16.8 16.1
Mean HAQ-DI score 1.5 1.5 1.5 1.5
Mean DAS28-4(ESR) 6.4 6.5 6.4 6.4
Mean CRP (mg/L) 17.5 17.3 16.2 17.9
Positive for rheumatoid factor, % 68.2 66.2 66.4 65.9
Positive for anti-CCP, % 74.8 64.0 74.8 65.1
Prior therapy, n (%)
 TNF inhibitor 16 (7.8) 14 (7.0) 12 (11.2) 10 (7.9)
 Non-TNF inhibitor biologic agent 3 (1.5) 4 (2.0) 1 (0.9) 3 (2.4)
 Disease-modifying drug other than MTX 114 (55.9) 115 (57.2) 66 (61.7) 80 (63.5)
Concomitant therapy, n (%)
 Glucocorticoids 125 (61.3) 129 (64.2) 63 (58.9) 77 (61.1)
 Lipid-lowering medication 10 (4.9) 10 (5.0) 6 (5.6) 6 (4.8)
  1. aBaseline values at the start of the double-blind study; includes patients who completed treatment with ADA 40 mg every 2 weeks or tofacitinib 10 mg BID in the blinded study (or discontinued treatment for reasons other than a tofacitinib-related serious adverse event (AE)) and then enrolled in the extension study and switched treatment with minimal washout (≤2 weeks after their last dose of study drug in the blinded study). CCP cyclic citrullinated peptide, CRP C-reactive protein, DAS28-4(ESR) Disease Activity Score for 28-joint counts based on the erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire-Disability Index, MTX methotrexate, RA rheumatoid arthritis, SD standard deviation, TNF tumor necrosis factor